What's the deal with this battered breast cancer biotech and is it a good deal?
News & Analysis: Puma Biotechnology
An analyst downgrade and a departing executive make for a bad day.
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
The most significant potential concern for the company's lone drug product arose.
There are risks to having only one marketed drug product.
Investors reacted with dismay over the terms of a license agreement.
The pharma company announced full-year 2018 operating results and multiple business updates.
The terms of a new partnership aren't as good as investors had hoped.
The company announced fourth-quarter and full-year 2018 earnings.
Third-quarter earnings suggest Nerlynx sales aren't going to meet expectations.
Sales of the company's lead drug just aren't living up to expectations.